<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1832">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05137314</url>
  </required_header>
  <id_info>
    <org_study_id>PLG0206-PJI-101</org_study_id>
    <nct_id>NCT05137314</nct_id>
  </id_info>
  <brief_title>Study in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)</brief_title>
  <official_title>A Phase 1b Open-Label, Dose-Escalating Study to Evaluate the Safety and Tolerability of PLG0206 in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Occurring After Total Knee Arthroplasty (TKA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peptilogics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peptilogics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn about the safety and effects of PLG0206 for treating&#xD;
      acute periprosthetic joint infections (PJI) in conjunction with the DAIR (debridement,&#xD;
      antibiotics and implant retention) surgical procedure for patients with acute periprosthetic&#xD;
      joint infections (PJI) after total knee arthroplasty (TKA) .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Peptilogics, Inc. is developing PLG0206 for the treatment of PJIs. PLG0206 is an engineered&#xD;
      antibacterial peptide (EAP) based on naturally-occurring antimicrobial peptides (AMPs).&#xD;
      Recent work on PLG0206 has documented that PLG0206 is a highly effective anti-biofilm agent,&#xD;
      in addition to its established activity against planktonic staphylococcus, both in vitro and&#xD;
      in a murine animal model of PJI.&#xD;
&#xD;
      PLG0206 will be investigated in this study for treatment of acute PJI in conjunction with the&#xD;
      DAIR procedure followed by the 6-week course of antimicrobial therapy that is&#xD;
      standard-of-care (SOC) in this indication.&#xD;
&#xD;
      Patients will be followed for approximately 1 year post treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Open-Label, Dose-Escalating</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of treatment emergent AEs</measure>
    <time_frame>approximately 1 year</time_frame>
    <description>the safety and tolerability of PLG0206 administered via an irrigation solution for the treatment of an acute PJI occurring after TKA during DAIR.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Joint Infection</condition>
  <arm_group>
    <arm_group_label>3 mg/mL PLG0206</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administered intraoperatively by local irrigation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg/mL PLG0206</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administered intraoperatively by local irrigation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLG0206</intervention_name>
    <description>PLG0206 is an engineered antibacterial peptide (EAP)</description>
    <arm_group_label>10 mg/mL PLG0206</arm_group_label>
    <arm_group_label>3 mg/mL PLG0206</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with well-fixed prosthesis;&#xD;
&#xD;
          -  Patients who have preoperative diagnosis of TKA-PJI ongoing no more than 4 weeks prior&#xD;
             to study drug administration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients for whom a DAIR procedure is not indicated;&#xD;
&#xD;
          -  Patients with loose prosthesis and/or surgical treatment requiring removal of&#xD;
             well-fixed, non-modular implants at screening;&#xD;
&#xD;
          -  Presence of a sinus tract(s) at screening;&#xD;
&#xD;
          -  Patients on chronic antibiotic therapy within 3 months of diagnosis of the PJI at&#xD;
             screening;&#xD;
&#xD;
          -  Patients with previous history or presence of osteomyelitis in the index limb;&#xD;
&#xD;
          -  Patients who have uncontrolled diabetes mellitus;&#xD;
&#xD;
          -  Patients who have anemia at screening;&#xD;
&#xD;
          -  Patients with body mass index &gt;40 kg/m2 at screening;&#xD;
&#xD;
          -  Patients who are immunosuppressed;&#xD;
&#xD;
          -  Patients who require therapeutic anticoagulation and/or antiplatelet therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Heather Ford</last_name>
    <phone>7243554065</phone>
    <email>heather.ford@peptilogics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Huang, MD</last_name>
    <phone>9365775770</phone>
    <email>david.huang@peptilogics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>WVU</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PJI</keyword>
  <keyword>knee infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Arthritis, Infectious</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

